DUO Microcatheter

K250960 · Rev Neuro, LLC · QJP · Sep 8, 2025 · Cardiovascular

Device Facts

• Record ID: K250960
• Device Name: DUO Microcatheter
• Applicant: Rev Neuro, LLC
• Product Code: QJP · Cardiovascular
• Decision Date: Sep 8, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.1250
• Device Class: Class 2

Intended Use

The DUO Microcatheter is intended for the selective placement of devices and/or fluids, such as contrast media, into the peripheral, coronary, and neuro vasculature during diagnostic and/or therapeutic procedures.

Device Story

DUO Microcatheter is a single-lumen, variable stiffness, disposable, sterile catheter; used for selective placement of diagnostic/therapeutic devices or fluids into peripheral, coronary, or neuro vasculature. Device features radiopaque distal markers and shaft for fluoroscopic visualization; hydrophilic coating on distal 80 cm reduces friction. Operated by clinicians under fluoroscopic guidance; advanced over appropriately sized guidewire. Output is the delivery of contrast media or placement of interventional devices. Benefits include precise navigation through tortuous vasculature to target sites. Supplied with steam shaping mandrel and peel-away introducer.

Clinical Evidence

Bench testing only. No clinical or animal studies conducted. Verification/validation included dimensional analysis, tensile strength, leak resistance, burst pressure, particulate characterization, coating integrity, torque strength, kink resistance, chemical compatibility, tip flexibility, trackability, luer testing, and radiopacity. All tests met acceptance criteria. Biocompatibility testing (ISO 10993) confirmed non-cytotoxic, non-hemolytic, non-thrombogenic, and non-pyrogenic status.

Technological Characteristics

Single-lumen, variable stiffness catheter. Materials: polymer jacket, stainless steel reinforcement, PTFE inner layer, platinum/iridium marker. Hydrophilic coating on distal 80 cm. Dimensions: 2.8F proximal/2.4F distal OD, 0.021" ID. Sterilization: 100% Ethylene Oxide (SAL 10⁻⁶). Complies with ISO 10555-1, ISO 80369-7, and ISO 10993.

Indications for Use

Indicated for selective placement of devices and/or fluids (e.g., contrast media) into peripheral, coronary, and neuro vasculature during diagnostic or therapeutic procedures.

Regulatory Classification

Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

Predicate Devices

• Trevo Trak™ 21 Microcatheter (K211594)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

September 8, 2025

REV Neuro LLC
Shiva Ardakani
RA/QA
7060 Koll Center Parkway, Suite 300
Pleasanton, California 94566

Re: K250960
Trade/Device Name: DUO Microcatheter
Regulation Number: 21 CFR 870.1250
Regulation Name: Percutaneous Catheter
Regulatory Class: Class II
Product Code: QJP, DQO, DQY
Dated: August 7, 2025
Received: August 8, 2025

Dear Shiva Ardakani:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K250960 - Shiva Ardakani
Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

{2}

K250960 - Shiva Ardakani
Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

# Naira Muradyan -S

Naira Muradyan, PhD
Assistant Director
DHT5A: Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices
OHT5: Office of Neurological and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K250960 | |
| Device Name DUO Microcatheter | |
| Indications for Use (Describe) The DUO Microcatheter is intended for the selective placement of devices and/or fluids, such as contrast media, into the peripheral, coronary, and neuro vasculature during diagnostic and/or therapeutic procedures. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

REV Neuro LLC
DUO Microcatheter 510(k) Notification

# 510(k) Summary (K250960)

[As required by 21 CFR 807.92]

# Submitter's Name / Contact Person

Submitter: REV Neuro LLC
7060 Koll Center Pkwy, Suite 300
Pleasanton, CA 94566

Contact Person: Shiva Ardakani
RA/QA
Phone: [phone] ext. 209
Email: [e-mail]

Date Prepared: August 4, 2025

# General Information

Trade/ Proprietary Name: DUO Microcatheter
Common Name: Catheter, Percutaneous, Neurovasculature
Regulatory Name: Catheter, Percutaneous, 21 CFR 870.1250 - Class II
Product Code: QJP

Trade/ Proprietary Name: DUO Microcatheter
Common Name: Catheter, Intravascular, Diagnostic
Regulatory Name: Catheter, Intravascular, Diagnostic, 21 CFR 870.1200 - Class II
Product Code: DQO

Trade/ Proprietary Name: DUO Microcatheter
Common Name: Catheter, Percutaneous
Regulatory Name: Catheter, Percutaneous, 21 CFR 870.1250 - Class II
Product Code: DQY

Predicate Device: Trevo Trak™ 21 Microcatheter (K211594)

# Indications for Use

The DUO Microcatheter is intended for the selective placement of devices and/or fluids, such as contrast media, into the peripheral, coronary, and neuro vasculature during diagnostic and/or therapeutic procedures.

# Device Description

The DUO Microcatheter is a disposable, single use, sterile device. The DUO Microcatheter is a single-lumen, variable stiffness catheter with radiopaque marker(s) on the distal end and a luer hub on the proximal end. The catheter shaft has a hydrophilic coating on the distal 80 cm to reduce friction during use. The radiopaque shaft and distal marker(s) facilitate fluoroscopic visualization.

Page 1

{5}

REV Neuro LLC
DUO Microcatheter 510(k) Notification

Device dimensions and configuration are shown on the product label. A steam shaping mandrel and a peel away introducer are provided with each microcatheter.

# Technological Characteristics and Product Feature Comparison

REV Neuro has demonstrated the DUO Microcatheter is substantially equivalent to the Predicate device, Trevo Trak™ 21 Microcatheter (K211594) based on the same or similar materials, similar design, and the same fundamental operating principles. A comparison of the Subject device with the Predicate device is summarized below.

| Device Attribute | Predicate Device | Subject Device |
| --- | --- | --- |
| | Trevo Trak™ 21 Microcatheter | DUO Microcatheter |
| 510(k) Number | K211594 | K250960 |
| Product Code | QJP, DQO, DQY | QJP, DQO, DQY |
| Regulation Number | 21 CFR 870.1250
21 CFR 870.1200 | 21 CFR 870.1250
21 CFR 870.1200 |
| Classification | II | II |
| Indications for Use | The Microcatheter is indicated for use in the selective placement of devices and/or fluids, such as contrast media, into the peripheral, coronary, and neuro vasculature during diagnostic and/or therapeutic procedures. | The DUO Microcatheter is intended for the selective placement of devices and/or fluids, such as contrast media, into the peripheral, coronary, and neuro vasculature during diagnostic and/or therapeutic procedures. |
| Device Description | The Microcatheter is a single-lumen, braided shaft, variable stiffness catheter with radiopaque marker(s) on the distal end and a luer hub on the proximal end. The catheter shaft has a hydrophilic coating on the distal 100 cm to reduce friction during use. The radiopaque shaft and distal marker(s) facilitate fluoroscopic visualization. | The Microcatheter is a single-lumen, variable stiffness catheter with radiopaque marker(s) on the distal end and a luer hub on the proximal end. The catheter shaft has a hydrophilic coating on the distal 80 cm to reduce friction during use. The radiopaque shaft and distal marker(s) facilitate fluoroscopic visualization. |
| Accessory Devices | Rotating Hemostasis Valve (RHV) | Peel Away Introducer, Steam Shaping Mandrel |
| Shaft Construction | Polymer jacket with Stainless Steel reinforcement and PTFE inner layer | Polymer jacket with Stainless Steel reinforcement and PTFE inner layer |
| Market Band | Platinum/ Iridium | Platinum/ Iridium |
| Outer Jacket Coating | Hydrophilic Coating | Hydrophilic Coating |
| Labeled Shaft Outer Diameters | 2.4F/ 2.0F | 2.8F proximal / 2.4F distal |

Page 2

{6}

REV Neuro LLC
DUO Microcatheter 510(k) Notification

| Device Attribute | Predicate Device | Subject Device |
| --- | --- | --- |
| | Trevo Trak™ 21 Microcatheter | DUO Microcatheter |
| Labeled Shaft Inner Diameter | 0.021” | 0.021” |
| Effective Length | 162 cm | 160 cm |
| Packaging Materials and Configuration | HDPE Packaging Hoop, Tyvek/Film Pouch, SBS Carton | HDPE Packaging Hoop and PETG with SIL Tray, Tyvek/Film Pouch, SBS Carton |
| How Supplied | Single Use/Sterile | Single Use/Sterile |
| Sterilization | EO Sterilization | EO Sterilization |
| Shelf Life | 2 years | 3 years |
| Principle of Operation | The device is advanced into the vasculature over an appropriately sized guide wire. Once the microcatheter is inserted, the catheter can be advanced through the vasculature to the desired location. | The device is advanced into the vasculature over an appropriately sized guide wire. Once the microcatheter is inserted, the catheter can be advanced through the vasculature to the desired location. |

## Testing Summary

## Performance Data – Bench Testing

The results of design verification and design validation testing conducted on the DUO Microcatheter demonstrate that it performs as designed, is suitable for the intended use, and is substantially equivalent to the legally marketed Predicate device. The design verification and design validation bench testing are summarized below.

| Test | Test Method Summary | Conclusion |
| --- | --- | --- |
| Dimensional Verification | The device dimensions were measured to confirm they meet design specifications. | Pass |
| Tensile Strength | Tensile strength was measured across material transitions based on ISO-10555-1. | Tensile strength was above acceptance criterion established by Trackability testing. |
| Air Leak Resistance | Air leak tested based on ISO 10555-1. | Pass |
| Liquid Leak Resistance | Liquid leak tested based on ISO 10555-1. | Pass |
| Burst Pressure | Burst pressure tested based on ISO 10555-1. | Static burst pressures were above acceptance criterion established by manual syringe delivery of contrast. |
| Particulate Characterization | Particulates were collected from a validated model, characterized, and compared to the predicate. | Particulate generation was comparable to the predicate device |

Page 3

{7}

REV Neuro LLC
DUO Microcatheter 510(k) Notification

| Coating Integrity | Hydrophilic coating was inspected before and after simulated use in a tortuous model. | Pass |
| --- | --- | --- |
| Torque Strength | The distal end of the catheter was constrained while the proximal end of the catheter was rotated in a model to verify that the catheter can withstand torsional load. | Pass |
| Kink Resistance | Kink resistance was tested for all applicable segments of the catheter. | Pass |
| Chemical Compatibility | Catheter was visually inspected before and after exposure to various clinically relevant chemicals. | Pass |
| Tip Flexibility | Tip stiffness tested per ISO 10555-1 at multiple locations and compared to the predicate. | Tip flexibility was comparable to the predicate device. |
| Distal Tip Configuration | The distal tip was inspected to verify it is smooth and rounded. | Pass |
| Surface Condition | Surface was inspected to verify the external surface of the catheter is free from extraneous matter, process or surface defects along the shaft. | Pass |
| Trackability | To evaluate the force required to track the catheter through a tortuous model compared to the predicate. | Pass |
| Luer Testing | Hub luer was tested to meet the requirements of ISO 80369-7. | Pass |
| Compatibility and Simulated use | The device was used in simulated anatomical model to assess overall performance and interaction with ancillary devices and stent retrievers. | Pass |
| Corrosion | Corrosion resistance was evaluated per ISO 10555-1. | Pass |
| Radiopacity | Radiopacity was evaluated under fluoroscopy in an in vitro model. | Pass |

## Performance Data - Animal Study, Clinical Study

No animal study or clinical study was conducted as bench testing was determined sufficient for verification and validation purposes.

## Shelf-Life Testing

The labeled shelf life for the DUO Microcatheter is three years. Shelf-life testing (product and packaging) and Distribution Shipping Challenge Conditioning and testing were performed on the Subject device, and the results met established criteria.

## Sterilization

The DUO Microcatheter and accessories are sterilized with 100% Ethylene Oxide. The DUO Microcatheter and accessories are provided sterile. A sterility assurance level (SAL) of 10⁻⁶ has been demonstrated. The DUO Microcatheter and accessories meet EO residuals per EN ISO 10993-7 for a limited contact delivery system – externally communicating. The DUO Microcatheter and accessories are for single use only.

Page 4

{8}

REV Neuro LLC
DUO Microcatheter 510(k) Notification

# Biocompatibility

The DUO Microcatheter was assessed for biocompatibility in accordance with ISO 10993-1, "Biological evaluation of Medical Devices – Part 1: Evaluation and Testing within a Risk Management Process". The Subject device is considered an externally communicating medical device with circulating blood contact for ≤24 hours. An overview of the biocompatibility testing is summarized below:

| Test/Method/Standard | Test Result | Conclusion |
| --- | --- | --- |
| Cytotoxicity (ISO 10993-5) | Non-Cytotoxic | Pass |
| Complement Activation (ISO10993-4) | Non-Activator | Pass |
| Hemolysis - Direct and Extract (ISO 10993-4) | Non-Hemolytic | Pass |
| Partial Thromboplastin Time (ISO 10993-4) | Comparable to Control | Pass |
| In Vitro Blood Flow Loop Assay (ISO 10993-4) | Non-Thrombogenic | Pass |
| Platelet Leukocyte Count (ISO 10993-4) | Non-Thrombogenic | Pass |
| Intracutaneous Reactivity (ISO 10993-23) | Non- Irritating | Pass |
| Sensitization /Maximization Test (ISO 10993-10) | Non-Sensitizing | Pass |
| Acute Systemic Toxicity (ISO 10993-11) | Non - Toxic | Pass |
| Material Mediated Pyrogenicity (ISO 10993-11) | Non- Pyrogenic | Pass |

# Conclusion

The DUO Microcatheter is deemed substantially equivalent to the predicate device (K211594) based on the same intended use/indications for use and similar design, materials, packaging, fundamental scientific technology, and operating principles. Performance testing and biocompatibility testing demonstrated that the DUO Microcatheter performs as intended. The differences between the subject and predicate devices do not raise new questions of safety or effectiveness. Therefore, the DUO Microcatheter is considered substantially equivalent to the predicate device.

Page 5